Skip to main content

Advertisement

Table 1 Nasopharyngeal carcinoma (NPC) and healthy control patient characteristics in the case–control and nested case–control studies

From: Decreased macrophage inflammatory protein (MIP)-1α and MIP-1β increase the risk of developing nasopharyngeal carcinoma

Characteristic Case–control study [cases (%)] Nested case–control study [cases (%)]
NPC patients Controls P value NPC patients Controls P value
Total 150 150   60 120  
Gender    1.000    1.000
 Male 130 (86.7) 130 (86.7)   35 (58.3) 70 (58.3)  
 Female 20 (13.3) 20 (13.3)   25 (41.7) 50 (41.7)  
WHO histological classification
 I 5 (3.3) NA   2 (3.3) NA  
 II 3 (2.0) NA   1 (1.7) NA  
 III 142 (94.7) NA   57 (95.0) NA  
Clinical stage
 Early (I + II) 51 (34.0) NA   35 (60.3) NA  
 Advanced (III + IV) 99 (66.0) NA   23 (39.7) NA  
 Unknown 0 NA   2 NA  
EBNA1/IgA
 Seronegative 52 (34.7) 120 (80.0) < 0.001 28 (46.7) 115 (95.8) < 0.001
 Seropositive 98 (65.3) 30 (20.0)   32 (53.3) 5 (4.2)  
  1. NA not applicable, NPC nasopharyngeal carcinoma, I squamous cell carcinoma, II differentiated nonkeratinizing carcinoma, III undifferentiated carcinoma, Early clinical stage I and clinical stage II, Advanced clinical stage III and clinical stage IV, EBNA1/IgA anti-Epstein–Barr virus nuclear antigen-1 immunoglobulin A antibody, seronegative the relative optical density (rOD) of the sample was < 1.5, seropositive the rOD of the sample was ≥ 1.5